leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 15:20:56 - browse：48876

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： HHS leader on health, climate change and biopharma emissions

leisure time

WSS

Nobel honors Karikó and Weissman's enduring partnership

Nobel honors Karikó and Weissman's enduring partnership

The United States is paying nearly triple for new Covid vaccines

The stability of $0 premiums in Medicare Advantage

RSV injection headlines need to be accurate for good uptake

Eli Lilly expects to double planned employment in Boston center

explore

leisure time

hotspot

Peter Hotez and the public health issue of online harassment

Lawsuit highlights wrinkle for disputes over surprise medical bills

Drug repurposing or repositioning? The language matters

WHO recommends second malaria vaccine

BioMarin wins approval for gene therapy to treat hemophilia A

Will Ozempic

23andMe had bad news about my health. I wish a person had delivered it

The explosion of genetic testing requires a new approach

Walensky prepares to leave CDC — and Congress — behind

Stop Congress from blocking public access to science

hotspot

The United States is paying nearly triple for new Covid vaccines

FDA gives detailed accounting of AI

CDC picks Alphabet's Verily for wasterwater surveillance contract

Congress extends some pandemic preparedness programs

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Senate committee scrutinizes Medicare Advantage brokers

focus

Wikipedia

leisure time

hotspot